| Alogliptin benzoate for the treatment of type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 22296609 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: Alogliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). It is one of several agents of this class now available for treatment of type 2 diabetes. Areas covered: This review is based upon a PubMed search and personal experience with alogliptin. The pharmacokinetics and pharmacodynamics of alogliptin are reviewed. The glucose-lowering effect of this agent is discussed as monotherapy and in combination with metformin, sulfonylurea, piogilitazone and insulin. The potential adverse effects of alogliptin are summarized. Alogliptin is compared with the other available DPP-4 inhibitors. Expert opinion: Alogliptin is an additional choice in the group of DPP-4 inhibitors. As a group, these agents have a relatively modest glucose-lowering effect, inferior to that of metformin, sulfonylureas, and insulin. They do not have the benefit of weight loss offered by the glucagon-like polypeptide (GLP)-1 agonists. The primary use of DPP-4 inhibitors is in combination with other hypoglycemic agents, mainly metformin. Their principal advantage is a low incidence of hypoglycemia, making these agents desirable in patients such as the elderly and those with cardiac disease. A greater use of alogliptin and other DPP-4 inhibitors will occur if long-term studies show reduced cardiac events or long-term retention of insulin secretory capacity. The Examine Trial, a large study of alogliptin in coronary disease patients, is now underway and could provide important supportive data. |
| | |
Authors:
|
Marc Rendell; Andjela Drincic; Radha Andukuri |
Related Documents
:
|
17443269 - Kidney growth, hypertrophy and the unifying mechanism of diabetic complications. 10439629 - Regulation of insulin-like growth factor-i in starvation and injury. 22544619 - Diabetes care practice patterns of recent pharmacy graduates. 6453129 - Effect of growth hormone on metaphyseal uptake of 99mtc-methylene diphosphonate. 1383069 - Phosphoribosyl pyrophosphate formation in the rat adrenal gland in relation to adrenal ... 8817849 - Diabetes mellitus in a dog with a growth hormone-producing acidophilic adenoma of the a... 18031169 - Immunological mechanisms in the aetiology of epilepsy: implications for treatment. 15579799 - Improved glycemic control in subjects with atypical diabetes results from restored insu... 22187639 - Healthy eating index and alternate healthy eating index among haitian americans and afr... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-1 |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: - ISSN: 1744-7666 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Creighton Diabetes Center , 601 North 30th Street, Omaha, NE 68131 , USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated ...
Next Document: Cost -effectiveness analysis for clinicians.